S

Researcher Profile

Sheng-jin Dou

1

Publications

108

Citations

10

Co-Authors

1

Active Years

Publications

Open Access Journal Article Nature Communications Sep 14, 2022

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Wu-tong Ju · Rong-hui Xia · Dong-wang Zhu · Sheng-jin Dou +16 more

10.1038/s41467-022-33080-8 108 citations

Publication Timeline

2022

1

Frequent Co-Authors